Tagast 41

Nice 13 trials 3 recruiting

13 Registered trials

3 Currently recruiting

Organisation

Tagast 41

Location

Nice, France

Identifier

ORG-100046166

Address

2 Boulevard Victor Hugo, 06000, France

Departments

#2056
#5001, Dermatologie
#5002
#7152:Dermatology & Venerology
#9160: Dermatology & Venerology
9202, Dermatologie
Dermatologie
Dermatology
Dermatology and Venerology Centre Azur - Nice
Liberal Cabinet TAGAST 41
NA
Private Derlatology Cabine

Clinical trials at this site (13)

Search interface

A Phase 3 extension study to assess the long-term safety and efficacy of remibrutinib in adult participants with moderate to severe hidraden… Pending

2025-523259-72-00 Hidradenitis Suppurativa (HS) 5
An Extension Study to Evaluate Safety, Efficacy, and Durability of Response to ESK-001 for Moderate to Severe Plaque Psoriasis (ONWARD3) Recruiting

2024-511166-36-00 Moderate to Severe Plaque Psoriasis 5 2025-06-13
A clinical trial to provide continued access to remibrutinib (LOU064) for people who are benefiting from it in a previous remibrutinib trial Recruiting

2025-524078-40-00 Chronic Spontaneous Urticaria 5 2026-06-10
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK) Recruiting

2023-503766-24-00 Moderate to Severe Plaque Psoriasis 11 2026-05-26
A Phase 3 study to assess efficacy, safety and tolerability of remibrutinib in adult and adolescent patients with moderate to severe hidrade… Ended

2024-513266-19-00 Hidradenitis Suppurativa (HS) 5 2025-06-13
Effectiveness and Safety of Lebrikizumab Treatment in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis Ended

2023-508235-31-00 Atopic Dermatitis 5 2024-06-17
52 weeks double-blind, double-dummy, randomized placebo-controlled trial to evaluate safety, efficacy and tolerability of remibrutinib in co… Ended

2022-502161-19-00 Chronic Spontaneous Urticaria 5 2024-03-12
An extension study of long-term efficacy, safety and tolerability of remibrutinib in chronic spontaneous urticaria patients who completed pr… Ended

2024-510818-33-00 Chronic Spontaneous Urticaria 5 2023-01-24
A Phase 4, Multi-centre, Randomized, Evaluator-blinded, Active-controlled Study to Determine the Incidence of Squamous Cell Carcinoma and Ev… Ended

2024-514394-22-00 Actinic Keratosis 6 2022-10-24
Phase 2a study to assess the efficacy and safety of GIA632 in adult participants with moderate to severe atopic dermatitis Halted

2025-521503-43-00 Atopic dermatitis 4 2026-02-12
Randomized, Double-Blind, Placebo and Active Comparator Controlled Phase 3 Study for Moderate to Severe Plaque Psoriasis to Evaluate Efficac… Ended

2023-508959-39-00 Moderate to Severe Plaque Psoriasis 5 2025-02-20
A trial to evaluate the efficacy and safety of different doses of LEO 138559 in adults with moderate-to-severe atopic dermatitis. Ended

2022-500777-14-00 Atopic Dermatitis 4 2023-11-06
A clinical study comparing different doses of a potential new medicine with an inactive medicine for patients with moderate to severe psoria… Ended

2023-508992-35-00 Plaque Psoriasis 4